DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG successfully concludes first Annual General Meeting as a stock listed company

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): AGM/EGM B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG successfully concludes first Annual General Meeting as a stock listed company 09.03.2017 / 18:41 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- BRAIN AG successfully concludes first Annual General Meeting as a stock listed company * New Supervisory Board members with high approval elected * Change of the auditor as planned * New Authorized Capital ensures high flexibility for corporate finance transactions * Frank Goebel new Chief Financial Officer (CFO) Zwingenberg, 9 March 2017: B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) today successfully held its first Annual General Meeting since the IPO on February 9, 2016. At the Annual General Meeting 70,77% of the total share capital, the latter accounting for 16,414,348 shares of BRAIN AG, was represented. All agenda items, including the new election of four Supervisory Board members, the election of a new auditor as well as the creation of a new Authorized Capital, were resolved by a large majority of the participating shareholders. After the return of Dr Georg Kellinghusen to the Supervisory Board, Mangement Board member Frank Goebel becomes CFO of BRAIN AG as previously announced. Dr Juergen Eck (CEO) particularly focused his speech on last year's IPO and the business strategy of the BRAIN Group, referring to BRAIN's two segments. Since the IPO, both segments were expanded further and new milestones have been achieved. As an example, he mentioned the start of the DOLCE program for the production of natural sweeteners with its high growth potential. "Our goal is to pursue the long-term growth path sketched out for the bioeconomy along with shareholders. We therefore went public at an early stage of our development. And this strategy so far has been successfull", explained Dr Juergen Eck. "The capital market is increasingly willing to contribute to the expansion of the future sectors around the bioeconomy and to participate in it. This is also due to the positive perception of the bioeconomy topics in public discussions." New auditor elected Pursuant to the regulations of the EU auditor regulation, BRAIN 2016 carried out a tender procedure for the determination of an auditor for the financial year 2016/17. The shareholders approved the proposal of the Supervisory Board to entrust Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft with this mandate. The auditor for fiscal year 2015/16, PricewaterhouseCoopers AG Wirtschaftsprüfungsgesellschaft, was therefore replaced. Change in the Supervisory Board At the Annual General Meeting, four of the six Supervisory Board members of BRAIN AG were to be newly elected. In addition to the re-election of Professor Dr Klaus-Peter Koller who has already been a member of the Supervisory Board for many years, Dr Anna Eichhorn, Dr Martin Jager and Dr Georg Kellinghusen were newly elected to the Supervisory Board. Dr Kellinghusen had already been a Supervisory Board member before his term in the Management Board, which started in January 2016. Creation of a new Authorized Capital BRAIN AG partially utilised its authorized capital during the IPO in the fiscal year 2015/16 as planned in an amount of EUR 3.5 million. Against this background, the Annual General Meeting followed the proposal of the Management Board and the Supervisory Board to create a new Authorized Capital in order to enable the company to remain flexible towards potential corporate finance transactions. Until 8 March 2022, the Management Board may increase the share capital once or several times by a nominal amount of up to EUR 8.2 million by issuing just as many new shares. Frank Goebel becomes Chief Financial Officer As previously announced at the end of the fiscal year 2015/16, the appointment of Dr Georg Kellinghusen as a member of the Management Board and Chief Financial Officer of BRAIN AG ended at the conclusion of the Annual General Meeting. Dr Kellinghusen played a major role during the successfull realisation of the BRAIN AG IPO and is now returning to the Supervisory Board. New CFO is Frank Goebel, who joined the BRAIN Group as managing director of the company's wholly-owned subsidiary BRAIN Capital GmbH in February 2015 and had been appointed to the BRAIN Management Board in November 2016. Dr Juergen Eck (CEO) and Frank Goebel (CFO) now form the two-man executive board of BRAIN AG. The detailed voting results and the presentation on agenda item 1 (in German language) are available for download on the company's website at www.brain-biotech.de/en/investor-relations/annual-general-meetings. About BRAIN BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars -"BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive -collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brainbiotech.de/en. Contact: B.R.A.I.N Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany Tel.: +49-6251-9331-16 Fax: +49-6251-9331-11 E-Mail: [email protected] www.brain-biotech.de Disclaimer This press release contains forward- looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAINAG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AGdoes not undertake any obligation to update or revise any forward-looking statements. --------------------------------------------------------------------------- 09.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 552691 09.03.2017

Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 21,13 22,79 24,11 27,05 38,56 38,23 0,00
EBITDA1,2 -3,10 -12,36 -7,70 -6,55 -2,50 -3,88 0,00
EBITDA-Marge3 -14,67 -54,23 -31,94 -24,21 -6,48 -10,15 0,00
EBIT1,4 -4,57 -13,81 -9,37 -9,57 -7,20 -8,23 0,00
EBIT-Marge5 -21,63 -60,60 -38,86 -35,38 -18,67 -21,53 0,00
Jahresüberschuss1 -5,47 -14,43 -9,40 -8,37 -11,12 -9,02 0,00
Netto-Marge6 -25,89 -63,32 -38,99 -30,94 -28,84 -23,59 0,00
Cashflow1,7 -4,11 -8,68 -5,80 -5,42 -3,38 -4,77 0,00
Ergebnis je Aktie8 -0,36 -0,97 -0,58 -0,45 -0,61 -0,52 -0,18
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 10,050 199,61
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 18,27 0,00 -21,11
11,25 - 5,22 -55,14
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
0,00 0,00 0,00 10.03.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.02.2021 28.05.2021 30.08.2021 14.01.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
7,05% 16,10% 11,17% 16,86%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN